SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00586651
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of
      CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with
      Essential Thrombocytosis (ET).
    
Name: lestaurtinib
Description: 60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
 Type: Drug
Group Labels:  1  lestaurtinib  
  
Primary Outcomes 
 Measure: Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study. Time: 18 weeks +
   
Secondary Outcomes 
 Measure: - improvements in hemoglobin values, neutrophil count, and platelet count. - reduction in dose of hydroxyurea - reduction in splenic enlargement - rate of phlebotomy Time: 18 weeks +
 
Purpose: Treatment
Allocation: N/A
Single Group Assignment 
There is one SNP
SNPs
1 V617F 
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation. --- V617F --- 
Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.. null. --- V617F --- 
-  The patient has a detectable JAK2 V617F mutation. --- V617F ---